Breast Cancer
An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
This interactive patient case simulation is designed to support risk stratification and treatment decision-making in HR+, HER2− early breast cancer (EBC).
This activity consolidates three educational infographics examining recurrence risk assessment, adjuvant CDK4/6 inhibitor clinical trial data, and adverse event management in patients with high-risk HR+, HER2− early breast cancer (EBC).
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
New ASCENT-04 data presented at ASCO 2026 suggest that first-line sacituzumab govitecan plus pembrolizumab may provide sustained clinical benefit beyond first progression in patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer. The exploratory post-hoc analysis showed improved PFS2 versus chemotherapy plus pembrolizumab, despite high crossover to sacituzumab govitecan in the control arm.
Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.
The plenary session at the AACR Annual Meeting 2026 brought sharp focus to one of oncology’s most urgent challenges: the global rise in early-onset cancers. Across four complementary presentations, speakers combined epidemiology, molecular biology and clinical insight to frame a multifactorial, and still evolving, picture of risk in younger populations. Below, we have broken down the key points and take-home messages from the session.
See who the oncology community selected as the rising stars of 2026!
In this Future Leaders interview, Dr Agostinetto discusses the mentors who shaped her career, the value of combining clinical care with research, and why collaboration and mentorship are essential for the next generation of oncologists.
At EBCC15, Dr Elisa Agostinetto presented compelling evidence that circulating tumor DNA (ctDNA) at completion of neoadjuvant therapy could be a game-changer biomarker for predicting breast cancer relapse. In the Q&A below, Dr. Agostinetto discusses the implications of her findings and the path toward integrating ctDNA into routine clinical practice.
The 15th European Breast Cancer Conference (EBCC15) showcased a wave of research poised to reshape breast cancer care. Below, we spotlight the key highlights from this year’s conference.
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
Breakthroughs from the 2025 San Antonio Breast Cancer Symposium in oral SERDs, HER2-targeted maintenance therapy, ADCs and next-generation endocrine combinations are reshaping breast cancer care across early and metastatic disease. From practice-changing phase III data to nuanced treatment selection in triple-positive and ESR1-mutant disease, this in-depth report unpacks what the latest trials really mean for clinicians. Register now to read the full analysis and stay ahead of rapidly evolving practice.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Discover how everyday choices—from what you eat to how you manage stress—can significantly shape long-term cancer prevention. This article explores the powerful, evidence-based impact of nutrition, physical activity, sleep, and social connection on lowering cancer risk and supporting healthier aging. Learn what the world’s longest-living communities can teach us about prevention—and why small lifestyle changes can make a big difference.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
